Human recombinant transforming growth factor a (TGFa), which binds to the epidermal growth factor (EGF) receptor and causes several biological effects similar to those caused by EGF, was compared with murine EGF for its effects on a number of parameters of bone cell metabolism. TGFa stimulated bone resorption in two organ culture systems, the fetal rat long bone and neonatal mouse calvarial systems. TGFa stimulated bone resorption at concentrations as low as 0.1 ng/ml. TGFa effects on bone resorption in mouse calvariae were inhibited by indomethacin, suggesting that, like EGF, its effects were mediated by prostaglandin synthesis. TGFa had a different time course of action on bone resorption from that of EGF, causing more rapid release of previously incorporated 45Ca from bone cultures, suggesting that TGFa does not function on bone as a simple EGF analogue. TGFa also caused effects on osteoblast function resembling those of EGF. It inhibited alkaline phosphatase activity in cultured rat osteosarcoma cells with the osteoblast phenotype and inhibited collagen synthesis in fetal rat calvaria at concentrations of 1.0 ng/ml. The lowest concentration of TGFa (expressed as nanogram equivalents of EGF per ml) required to produce a response in all of the systems tested was about 1/10th of that needed for EGF to produce a similar effect. These results indicate that TGFa is a potent stimulator of bone resorption and inhibitor of bone formation as assessed by inhibition of collagen synthesis and alkaline phosphatase activity and are consistent with the hypothesis that TGFa may be responsible, at least in part, for the bone resorption associated with some tumors.
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Transforming growth factor alpha (TGFa) is secreted by a variety of human and rodent tumor cells and binds to the epidermal growth factor (EGF) receptor. TGFa causes many of the known biological effects of EGF (1) (2) (3) . Multiple peptides of different molecular weights with TGFa activity (as assessed by inhibition of EGF binding and stimulation of anchorage-independent growth) have been detected in culture media and extracts of tumor cells. A small species of 50 amino acids has been purified (4, 5) . It is about 40% homologous with EGF (4, 6) . Cloning of the cDNA reveals that it is initially synthesized as a larger precursor, which undergoes subsequent posttranslational cleavage. Proper engineering of the sequence coding for the 50 amino acid TGFa has allowed the expression of biologically active human TGFa in Escherichia coli (6) .
EGF causes osteoclastic bone resorption (7, 8) and inhibits bone formation as assessed by collagen synthesis in organ cultures of fetal rat calvariae (7) (8) (9) and alkaline phosphatase activity in osteoblast-like cells (10) . Since EGF stimulates osteoclastic bone resorption and TGFa competes with EGF for the same receptor, it has been suggested that tumor production of TGFa could be responsible for the bone destruction that is associated with some neoplasms (11, 12) . Partially purified bone-resorbing activity associated with an animal tumor contains TGFa activity (11) , and this tumorderived bone-resorbing activity is inhibited by antisera to the EGF receptor (13) , which blocks the biological effects of EGF and TGFa (14) , indicating that the bone-resorbing factor is dependent on availability of the EGF receptor for its biological effects. In this report, we have compared the effects of human recombinant TGFa and murine EGF on a number of parameters of bone cell metabolism. TGFa appeared to be more potent than EGF in these systems and had a different time course of action on bone resorption. These results indicate that TGFa does not act on bone as a simple homologue of EGF.
MATERIALS AND METHODS
Bone Resorption Assays. The bone resorption assay has been described (15) . Briefly, rats at day 18 of gestation were injected subcutaneously with 200 ,Ci (1 Ci = 37 GBq) of 45CaC12. The following day the fetuses were removed, and the tubular mineralized shafts of the radii and ulnae were dissected free from the cartilagenous ends and surrounding soft tissue. The explanted shafts were precultured in BGJb medium (Irvine Scientific) for 18 (21) .
Recombinant TGF. The 50-amino acid TGFa was expressed in E. coli as described (6) , purified by Sephadex G-75 gel filtration followed by HPLC, and assessed for biological activity by its capacity to compete with labeled EGF for binding to the EGF receptors on mink lung cells (CCL 64) and for the capacity to stimulate growth of NRK (normal rat kidney) indicator cells in soft agar (6) . Concentrations of TGFa in terms of nanogram equivalents of EGF were measured by determining the amounts of TGFa required to displace labeled EGF from its receptors on mink CCL 64 lung fibroblasts (6) or from UMR 106 osteosarcoma cells (11) , which were used to verify the equivalence of TGFa and murine EGF preparations used in the experiments.
RESULTS
Bone Resorption. Fetal rat long bones. Human recombinant TGFa stimulated bone resorption in a concentrationdependent manner (Fig. 1) . Maximal activity was obtained with a concentration of TGFa of approximately 30 ng equivalents of EGF per ml over a 5-day incubation period. Bone resorption was stimulated by concentrations of TGFa as low as 3 ng equivalents of EGF per ml. The maximum value obtained with 30 ng of EGF per ml was comparable to the effect induced by a concentration of TGFa lower by 1 order of magnitude. In addition the maximal responses with EGF were always less than those obtained with TGFa (Fig.  1) . The results shown in Fig. 1 are from a single experiment representative of data obtained on four separate occasions.
The time course of action of TGFa also was compared with that of EGF (Fig. 2) . The results shown are from one experiment representative of data obtained from three experiments. It was observed that TGFa stimulated bone resorption within 48 hr at concentrations of 30 ng of EGF equivalents per ml and more, whereas EGF had no statistically significant effect over this time period at the concentrations tested (1-300 ng/ml). In the fetal rat long bone assay, the bone-resorbing activity of TGFa appeared to be inde- pendent of prostaglandin production by the bone because the prostaglandin synthesis inhibitor indomethacin (1 ,uM) had no effect on the bone-resorbing activity of TGFa in two separate experiments (data not shown). Indomethacin at this concentration totally inhibited PGE production as measured by radioimmunoassay. PGE concentrations were 1.4 0.01 ng/ml in control cultures and 1.1 0.01 ng/ml in TGFatreated cultures. Treatment with indomethacin reduced medium PGE concentrations to <0.01 ng/ml. Similar results have been described for EGF in this assay system (8) .
Neonatal mouse calvariae. TGFa and EGF also stimulated bone resorption in the calvariae bioassay system (Tables 1  and 2 ). The concentrations of both TGFa and EGF required were lower than those required to stimulate resorption in the fetal rat long bone system. The lowest concentration of TGFa required to produce a significant effect were at most 1/10th of the concentration of EGF. There was, however, no difference in the maximal responses obtained with TGFa and EGF. In the calvariae assay, we found that bone resorption stimulated by TGFa and EGF was strongly inhibited by indomethacin (1 ,uM) ( Table 2 ). Data shown are from one experiment and representative of data obtained from three experiments.
Because the TGFa was produced in E. coli, the possibility existed that the TGFa preparation might contain endotoxin, Experiments were carried out as described. TGFa concentrations are expressed as ng equivalents of EGF per ml. In experiment 4, the bones were incubated for 96 hr. In the other experiments, they were incubated for 72 hr. Each result is expressed as the mean ± 1 SEM (four half calvariae per group). *Significantly greater than 1.0; P < 0.05. tSignificantly greater than 1.0; P < 0.01. which has previously been shown to stimulate bone resorption (22) . For this reason, we tested control medium and medium containing maximally active concentrations of TGFa for the presence of endotoxin (23) . We found no difference in the concentration of endotoxin between control and TGFa-containing medium.
Alkaline Phosphatase Content in Osteoblast-Like Cells. TGFa and EGF caused a concentration-dependent inhibition of alkaline phosphatase activity in cultures of rat osteosarcoma cells that have the osteoblast phenotype (Table 3) . Data shown are from one experiment representative of results found on three separate occasions. An inhibition of alkaline phosphatase activity could be obtained with both TGFa and EGF. However, the minimum concentration of the growth factor needed for this effect in the case of TGFa is clearly lower (perhaps by factors of 3-10) than for EGF.
Collagen Synthesis in Fetal Rat Calvaria. In the collagen synthesis assay, TGFa was also significantly more effective in inhibiting collagen biosynthesis than was EGF (Table 4) . Data shown are from one experiment representative of data obtained in three experiments. The lowest concentration at which TGFa clearly inhibited collagen synthesis was at 1 ng/ml. In contrast, EGF at 1 ng/ml had no significant effect on collagen synthesis. The lowest concentration tested at which EGF caused significant inhibition of bone collagen synthesis was 10 ng/ml. TGFa and EGF had no significant effect on noncollagen protein synthesis. Over longer incubation periods (96 hr), TGFa continued to inhibit collagen synthesis and was effective at doses as low as 1.0 ng/ml (Table 4) . Inhibition of collagen synthesis does not appear to Experiments were carried out as described. EGF concentration is expressed in ng/ml. TGFa concentration is expressed in ng equivalents of EGF per ml. Results are expressed as means ± 1 SEM (n = four half calvariae per group). Indo, indomethacin. *Significantly greater than corresponding control; P < 0.05. be a result of increased cell proliferation and loss of differentiated function. Concentrations of TGFa between 30 and 1 ng/ml inhibited collagen synthesis by 40% (Table 4) but had no significant effect on thymidine incorporation into the calvariae (data not shown).
DISCUSSION
The results of these experiments show clearly that TGFa is a potent osteotropic agent. TGFa stimulates bone resorption as measured by the 45Ca release and inhibits bone formation in vitro as assessed by inhibition of collagen synthesis in organ cultures and alkaline phosphatase activity of cells with the osteoblast phenotype, which contain EGF receptors. In general, the concentrations of TGFa (as expressed in nanogram equivalents ofEGF) required to cause these effects were 1 order of magnitude less than that required for EGF to produce similar effects.
One of the interesting facets of this study is the comparison between TGFa and EGF effects on bone. EGF and TGFa share approximately 40% homology (4) , and TGFa has biological properties of EGF in vitro. TGFa binds to the EGF receptor, and its biological effects on indicator cells in soft agar can be inhibited by specific antisera that block the EGF binding site on the EGF receptor (14) . Our data indicate that the effects of TGFa are qualitatively similar to EGF on bone The results of this study emphasize the apparent difference in sensitivity between the two bioassay systems for bone resorption that we used. Although we found that both TGFa and EGF resorb bone in each of the models, the mouse calvarial system was approximately 1 order of magnitude more sensitive to both growth factors than was the rat long bone system. This had been suggested previously by the independent studies of Tashjian and Levine (7), who used mouse calvaria, and Raisz et al. (8) , who used the fetal rat long bone system, with EGF. There were other differences noted between these models. Tashjian and Levine (7) found that EGF-mediated resorption of bone was dependent on prostaglandin generation by the bone cultures, whereas Raisz and colleagues (8) using the rat long bone system found that bone resorption occurred independent of prostaglandin synthesis. These two assay systems have been the major in vitro bone resorption systems studied over the past differences between them clearly need to be clarified. In general, the similarity of responses of the two systems has been remarkable. Differences between them are probably due to variations in cell populations that comprise the calvariae ofthe neonatal mouse and the long bones ofthe fetal rat at day 19 of gestation.
Increased bone resorption associated with inhibition of bone formation is the histologic change in bones usually seen in animal models as well as patients with humoral hypercalcemia of malignancy (12) . Quantitative bone histomorphometry shows increased osteoclastic bone resorption and inhibition of bone formation in this syndrome (27) . These observations are consistent with the hypothesis that the tumor-derived osteotropic product responsible for hypercalcemia of malignancy in some tumors is TGFa or a factor that has identical biological effects on bone to those of TGFa. We have convincing evidence in one animal model of humoral hypercalcemia that TGFa itself is the mediator of bone resorption. In this case, the biological activity of TGFa copurified with bone-resorbing activity (11) and the tumorderived bone-resorbing activity can be blocked by antisera to the EGF receptor, which block the binding of EGF as well as the biological effects of EGF and TGFa (13) .
Note. Since the original submission ofthis manuscript, Tashjian et al. (28) have reported that human recombinant TGFa stimulates resorption of neonatal mouse calvariae by a prostaglandin-dependent mechanism.
